Visualization of cortical MS lesions with MRI need not be further improved -No Caterina Mainero and Tobias Granberg
Cortical lesions are an established pathological feature of multiple sclerosis (MS) and one of the main substrates of MS disease progression. 1 Despite recent advances in imaging using ultra-high-field strength magnetic resonance imaging (MRI), histopathological-MRI correlative examinations show that a variable proportion of cortical lesions go undetected at visual examinations of MRI scans. 2, 3 This affects predominantly subpial lesions, the most common cortical lesional histopathological type in MS, located in the juxtameningeal cortical layers. 1 Here, we argue that further improvement of visualization of cortical MS lesions with MRI, particularly the subpial type, is needed to better understand cortical MS lesion pathogenesis and its role in neurodegeneration and, in clinical practice, for increasing the sensitivity and specificity of MS diagnosis, as well as for monitoring disease progression and treatment response in patients with definite MS.
Knowledge of cortical lesion pathogenesis in MS is limited and mostly derives from post-mortem examinations of MS brains. Pathological studies report that the histopathological and immunological characteristics of cortical lesions seem to differ significantly from those observed in the white matter (WM), suggesting a location-dependent expression of the MS immunopathological process. 1 The inherent cross-sectional study design of pathological examinations, which does not lend itself to prospective repeated measures, prevents from temporal observations of suspected pathophysiologic pathways, which in turn could help to establish etiologic causation in cortical lesion development as well as differences from neuropathological processes occurring in WM. Additionally, post-mortem studies tend to skew tissue samples toward older individuals with established disease and with possible comorbidities that may confound the analysis, while under-representing early disease. Improvements in cortical lesion visualization in vivo would be extremely valuable for monitoring longitudinally cortical lesion dynamics from the earliest MS disease stages and for assessing their relationship with underlying WM pathology as well as their independent contribution to neurodegeneration and to the establishment of irreversible disability.
Improvements in cortical lesion visualization in vivo, especially the subpial histopathological type, could also increase the sensitivity and specificity of MS diagnosis and aid in differential diagnosis. A recent review of MS diagnostic criteria suggested incorporating cortical lesions assessment in the dissemination in space criteria for MS, as an extension to the current inclusion of juxtacortical lesions. 4 Cortical lesions can indeed be detected in about one-third of patients with clinically isolated syndrome and are able to independently predict conversion to MS. 5 Cortical lesions have been observed, with a similar prevalence, in a small cohort of cases with radiologically isolated syndrome in association with other imaging markers of evolution to MS, 6 indicating that in individuals with incidental asymptomatic WM abnormalities on MRI, the presence of cortical lesions can increase the confidence for the attribution of the imaging findings to the spectrum of demyelinating diseases. 4 Importantly, cortical lesions, and specifically the subpial type, have been suggested to represent a diagnostic hallmark of MS as they are neither seen in other central nervous system (CNS) diseases that can induce WM changes, such as neuromyelitis optica and migraine, 4 nor in chronic inflammatory or neurodegenerative brain disorders. 7 Visualization of subpial demyelinating lesions with MRI, unfortunately, remains a challenge. While the development, at conventional field strengths, of gray matter-specific pulse sequences (double inversion recovery, phase-sensitive inversion recovery) has greatly improved cortical lesion detection in vivo, such imaging protocols are still suboptimal for visualizing subpial demyelination. Subpial lesions can be imaged with superior sensitivity and spatial specificity at ultra-high-field 7 Tesla (7T) MRI. 2, 3, 8, 9 Ultra-highfield strength provides increased lesion conspicuity since the higher signal-to-noise ratio may be used to increase contrast and/or resolution. Furthermore, the increased T 2 * effects with higher field strengths can be used to improve the delineation of cortical substructure. 2, 3 Initial clinical studies show that focal cortical lesions seen on 7T MRI independently contribute to physical and cognitive disability in MS and that cortical lesions are a more sensitive correlate of clinical outcome than cortical atrophy. 8, 9 At 7T ultra-high resolution, quantitative MRI assessments of cortical integrity, however, reveal that cortical pathology, especially in progressive disease, is also present in the normal appearing cortex, expanding well beyond visible cortical lesions. 10 The clinical impact of this "hidden" cortical pathology is still unclear. While quantitative MRI methods are promising for investigating the presence of diffuse cortical MS pathology beyond focal lesions, including that affecting the juxtameningeal cortical layers, they require extensive post-processing making their application in clinic limited. Their use at lower field strength is also hampered by long scan acquisition times, which are necessarily required to achieve sub-millimeter cortical resolution needed to avoid partial volume effects with adjacent WM and cerebrospinal fluid.
7T scanners are becoming more common, and the first system planned for clinical use has been launched recently, which will make ultra-high-field MRI more available for clinical research and practice. Histopathological verifications of the ability of different pulse sequences at ultra-high-field MRI to detect cortical lesions in ex vivo MS brains, however, report contrasting prospective and retrospective sensitivities even when comparing the same magnetic resonance (MR) contrasts. 2, 3 This indicates that there is still a need for optimization and standardization of imaging protocols across centers. Image interpretation also needs observer training and standardization of reading procedures. Additionally, the MR contrasts used in previous studies do not accurately distinguish the different pathological processes that characterize cortical MS lesions and that, in addition to demyelination, may include microglia activation and even remyelination. Efforts should be directed at increasing pathological specificity of MRI in the evaluation of cortical lesions in MS. This could be achieved by either combining multiple MRI contrasts or by complementing MRI with other imaging modalities, such as positron emission tomography, able to target specific molecular and/or cellular components of cortical pathology in MS. An accurate delineation of the heterogeneous cortical pathological processes could also help understanding the role of inflammation in cortical lesion development, which is still a matter of debate. Finally, it could help identifying selective "targets" for evaluating the response to existing treatments and for facilitating development of novel therapeutic approaches.
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Visualization of cortical MS lesions with MRI need not be further improved -Commentary Daniel S Reich
As translational scientists and as caregivers for people with multiple sclerosis (MS), we should spend our time asking-and answering-questions that are relevant to understanding the disease, finding ways to prevent it, and ameliorating its deleterious effects. Some of those questions are as follows: How and why does the disease start? How do lesions form? How do they repair? What biological pathways are common across people with MS and can also be targeted pharmacologically? How can we most efficiently decide whether a new drug is effective, both on a population level and in individuals? What can we tell a person sitting in our clinic about how his or her disease is likely to play out?
Sometimes, we can answer these questions by marshaling technologies that are already available, either in the lab or in the clinic, and applying them in clever ways. Sometimes, however, the answers point to new biology and demand new ways of assessing that biology-and in those instances, new technologies must be developed. But the target is always the biology. In this sense, the question of whether visualization of cortical lesions with magnetic resonance imaging (MRI) should be improved is fundamentally misplaced.
In their essays, Geurts and Chard, and Mainero and Granberg, implicitly recognize this tension. Geurts and Chard state explicitly that "we should keep in mind the reasons" for improving visualization of cortical lesions and suggest that such reasons should not include the ability to count ever higher numbers of lesions. Mainero and Granberg concur that lesion count per se is not the target, instead putting front and center the question of "pathological specificity" and pathophysiology. In these claims, both pairs of authors are right.
Both conceptually and practically, cortical lesions present an interesting challenge. Conceptually, the cortex-like the white matter-is not a uniform structure, despite its relatively homogeneous appearance on clinical MRI scans. It has unique cytoarchitecture and myeloarchitecture, and both architectures vary across gyri, lobules, and lobes. The cortex has a complex relationship with the underlying white matter and overlying leptomeninges, and the network of blood vessels that supply and drain the cortex is both intricate and spatially heterogeneous. All of these factors may play a role in whether, and how, cortical lesions develop. The most obvious example involves the subpial lesions, which radiate downward from the pial surface and often flank both banks of a single sulcus; the topography of such lesions is obviously different from that of the leukocortical and small intracortical lesions.
Indeed, one might argue that lesion classification should not depend on the (coarsely defined) tissue
